Conquest Research | Winter Park, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key inclusion criteria for part 1, 2 and 3:
Inclusion criteria for Part 4:
Key exclusion criteria for part 1, 2 and 3:
Exclusion criteria for Part 4:
Primary purpose
Allocation
Interventional model
Masking
285 participants in 21 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number: BP42155 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal